Idorsia shareholders voted in favor of all proposals by the Board

At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities.

The meeting was attended by 201 shareholders, representing a total of 90,297,668 shares, or 47.78% of the total outstanding shares.

Led by the Chairman of the Board, Mathieu Simon, and Jean-Paul Clozel, who was the Chief Executive Officer for the year under review, the company presented the progress being made by the team at Idorsia.

Mathieu Simon, MD, new Vice-Chairman and Lead Independent Director of Idorsia, commented:
“In the last seven years Idorsia has made huge progress on all fronts. We have brought three drugs to the market, built a global marketing organization, and launched QUVIVIQ in the US and main European countries. In addition, we created a late-stage pipeline, continued to discover new drugs, re-acquired aprocitentan from Johnson & Johnson, and secured financing for all these achievements. It is reassuring to see that our shareholders appreciate what has been achieved and believe in the future of Idorsia by giving the new management team and the Board their endorsement through their votes. I would like to welcome Bart Filius to the board and congratulate Jean-Paul for election as Chairman. I’m confident that with the new composition, we are well prepared for the next chapter of Idorsia’s story.”

Jean-Paul Clozel, MD, new Chairman of the Board of Directors, commented:
“I would like to thank our shareholders for the trust they place in the Board and in me as the new Chairman. Today, a new phase will begin for Idorsia. In the coming months, the priorities will be to finance Idorsia, improve the commercial performance with QUVIVIQ, prepare for the launch of TRYVIO, and reinforce the pipeline. I am confident that Idorsia will soon return to a situation where the priority will be scientific and commercial excellence rather than financing. This will require the full commitment of the whole Idorsia team, and as a Board we are here to support them wherever needed.”